Scientific deep-dive

The Cochrane Verdict, and Who Funded the Evidence

Two WHO-funded Cochrane reviews find weight loss likely to be sustained; the semaglutide review calls it clinically relevant. Both also note the trials were paid for by the manufacturers: all of them, in tirzepatide's case.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·3 citations

Cochrane, whose reviews grade how certain the evidence is for each outcome, has now reviewed semaglutide and tirzepatide for obesity, funded by the World Health Organization. Both reviews conclude the drugs produce weight loss that is likely to be sustained, and the semaglutide review calls that loss clinically relevant. Both also end on the same observation: the evidence base was paid for by the companies selling the drugs.[1][2]

What they concluded about weight

Start with the positive finding, because it is the main one. Semaglutide produces a clinically relevant weight loss at medium-term follow-up compared with placebo, likely sustained in the long term while taking the drug.[1] Tirzepatide likewise produces weight loss at medium-term follow-up, likely sustained longer term.[2]

That is Cochrane language, and Cochrane does not hand out “clinically relevant” casually. On the question these drugs are prescribed for, the answer is yes.

What they could not conclude

Everything else is where the certainty drains away, and the pattern is consistent across both reviews.

Outcomes beyond weight, as graded by the Cochrane reviews. Note how much rests on single studies.
OutcomeFindingCertainty
Semaglutide — quality of life, major cardiovascular events, mortalityEffects likely limited or uncertainDowngraded for risk of bias and imprecision
Tirzepatide — quality of life (SF-36 physical)MD 2.70 (95% CI 0.00 to 5.40), 1 study, 1,032 participantsLow
Tirzepatide — mortalityRR 0.83 (95% CI 0.22 to 3.17), 1 study, 1,032 participantsLow
Look at that quality-of-life interval. It runs from 0.00 to 5.40, so its lower bound sits exactly on no difference at all, and it comes from a single trial. A drug that reliably removes a fifth of someone’s body weight has not yet been shown, at any decent level of certainty, to make them feel better. That gap between the scale and the person is where this field stands.

The funding sentence

Both reviews say it, and Cochrane does not editorialize. For semaglutide: most studies were funded by the drug’s manufacturer, raising important concerns about conflicts of interest.[1] The tirzepatide review is blunter: all of the included studies were funded by the drug manufacturer.[2]

Not most. All.

This is not an accusation that anyone falsified anything, and it should not be read as one. Industry funds most drug trials, because trials are expensive and regulators require them. But industry-funded trials systematically choose the questions, the comparators, the endpoints and the durations that suit the sponsor, and across medicine they report more favorable results than independent ones.[3] Both reviews call for independent studies, particularly in underrepresented populations.[1][2]

What this changes for a reader

  • The weight claim is solid. Two conservative reviews agree, and it is the claim these drugs are sold on.
  • Claims beyond weight deserve more skepticism than they usually get. On quality of life and mortality the evidence is thin or graded low.
  • “While taking the drug” is doing real work in the semaglutide conclusion. Our maintenance trial article covers what happens when people stop.
  • Independent evidence is coming. The semaglutide review identified 46 ongoing studies that may strengthen future syntheses.

When a seller cites “the evidence” at you, remember that in the tirzepatide case it was entirely funded by the company that makes the drug. That does not make it wrong, but it is a reason to want more.

Frequently Asked Questions

That both produce weight loss at medium-term follow-up that is likely to be sustained longer term. The semaglutide review calls that loss clinically relevant and adds that it holds while the drug is taken. Effects on other outcomes (quality of life, cardiovascular events and mortality) were graded as limited, uncertain or low certainty.
The manufacturers. Cochrane notes that most semaglutide studies were funded by the drug's manufacturer, raising important concerns about conflicts of interest, and that all included tirzepatide studies were manufacturer-funded. Both reviews call for independent research.
No, and it should not be read that way. Industry funds most drug trials because regulators require them and they are expensive. But sponsors shape which questions, comparators, endpoints and durations get studied, and industry-funded trials across medicine report more favorable results than independent ones.
That has not been established at a useful level of certainty. For tirzepatide the estimate came from a single trial with a confidence interval running from 0.00 to 5.40, with its lower bound sitting exactly on no difference. For semaglutide, Cochrane described effects on quality of life as likely limited or uncertain.
The semaglutide review identified 46 ongoing studies. Both reviews specifically call for further independent studies, particularly in underrepresented populations.

References

  1. 1.Bracchiglione J, Meza N, Franco JV, et al. Semaglutide for adults living with obesity Cochrane Database of Systematic Reviews. 2026. PMID: 41161683.
  2. 2.Franco JV, Guo Y, Varela LB, et al. Tirzepatide for adults living with obesity Cochrane Database of Systematic Reviews. 2026. PMID: 41161687.
  3. 3.Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L Industry sponsorship and research outcome Cochrane Database of Systematic Reviews. 2017. PMID: 28207928.

MOTS-c: What the Evidence Shows, and What FDA Found

MOTS-c slowed weight gain and improved insulin sensitivity in mice. No published trial has given it to people, and there is no established human dose. The 503A bulks list leaves it out; under an interim HHS policy dated October 2026, HHS does not intend to take enforcement action against 503A compounding under strict conditions.

11 min read

GLP-1 Drugs After 65: Strength, Not Just Weight

Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite, and a 2024 review found no concise guidelines for this age group.

7 min read

Best Injection for Weight Loss? Every Approved Shot, Ranked on Trial Data

Zepbound took off the most weight of any injection FDA has approved for weight, and beat semaglutide head to head. Wegovy has the proven cardiovascular benefit. Label and trial data on weight, side effects and dropouts, plus what is not approved yet.

8 min read

Holding a GLP-1 Before Endoscopy or Surgery: What the Trial Found

A 2026 randomized trial put retained stomach contents at 3.1% when one dose was held against 25.0% when it was not, and found something more useful about the day-before diet.

7 min read

Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went

Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.

10 min read

Ozempic and the Vagina: Dryness, Odor and Yeast Infections

No GLP-1 label lists a vaginal side effect. Genital yeast infections belong to SGLT2 diabetes drugs such as Jardiance, and GLP-1 users had fewer of them in cohort studies. What FDA reports show, likely causes of dryness and odor, and when to see a clinician.

11 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.1

Collective

From $69/mo + membership

Get started →
Read full review →
7.9

Luvo Health

Moving between compounded and brand without changing seller

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →